Amendments to the Claims

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims

1. (Canceled)

2. (Currently Amended) A method of treating a type of cancer, comprising administering to a subject in need of such treatment a composition comprising a population of complexes, said complexes comprising (a) alpha-2-macroglobulin and (b) antigenic peptides, wherein said population of complexes was produced by a method comprising

(1) subjecting a protein preparation to (i) digestion with one or more proteases or (ii) cleavage by one or more non-enzymatic methods to produce a population of antigenic peptides,

wherein said protein preparation comprises total cellular proteins, total cytosolic proteins, total membrane-bound proteins, or total protein in a cellular fraction, of cells of said type of cancer, wherein said cellular fraction is selected from the group consisting of a membrane fraction and an organelle fraction; and ~~comprises at least 50 different proteins present~~

(2) complexing the population of antigenic peptides to alpha-2-macroglobulin in vitro; and

administering to said subject at least one treatment modality that does not comprise a heat shock protein or alpha-2-macroglobulin.

3-8. (Canceled)

9. (Previously Presented) The method of claim 2, wherein said complexing of the population of antigenic peptides to the alpha-2-macroglobulin is via formation of a covalent bond.

10. (Previously Presented) The method of claim 2, wherein said complexing of the population of antigenic peptides to the alpha-2-macroglobulin is via formation of a non-

covalent bond.

11-16. (Canceled)

17. (Previously Presented) The method of claim 2, wherein said population of complexes is purified.

18. (Canceled)

19. (Previously Presented) The method of claim 2, wherein the cells of said type of cancer are from a metastasis.

20. (Previously Presented) The method of claim 2, wherein said type of cancer is a metastasis.

21-22. (Canceled)

23. (Previously Presented) The method of claim 2, wherein the at least one treatment modality comprises a chemotherapeutic agent, an anti-angiogenic agent, a cytokine, a biological response modifier, a hormone, an antibody, a polynucleotide, an immunostimulatory oligonucleotide, a photodynamic therapeutic agent or radiation.

24. (Canceled)

25. (Previously Presented) The method of claim 2, wherein said composition is administered before, concurrently with, or after administration of the at least one treatment modality.

26. (Previously Presented) The method of claim 2, wherein the subject has previously been non-responsive to treatment with said at least one treatment modality in the absence of said composition.

27. (Previously Presented) The method of claim 2, wherein said administering of said composition is repeated at weekly intervals.

28. (Previously Presented) The method of claim 2, wherein said administering of said composition is repeated at the same site of the subject.

29. (Previously Presented) The method of claim 2, wherein said administering of said composition is intradermally or subcutaneously.

30. (Previously Presented) The method of claim 2, wherein a sub-optimal amount of said composition is administered.

31. (Previously Presented) The method of claim 2, wherein a sub-optimal amount of said at least one treatment modality is administered.

32. (Previously Presented) The method of claim 2, 17, 23, 26, 30, or 31, wherein the subject is human.

33-34. (Canceled)

35. (Previously Presented) The method of claim 2, wherein the antigenic peptides are autologous to the subject.

36-39. (Canceled)

40. (Previously Presented) The method of claim 2, 17, 23, 26, 30, or 31, wherein the composition comprises one or more adjuvants in admixture with said population of complexes.

41. (Previously Presented) The method of claim 40, wherein the one or more adjuvants is selected from the group consisting of QS-21, poly[di(carboxylatophen-oxy)phosphazene, monophosphoryl lipid A, muramyl dipeptide, threonyl- muramyl dipeptide, a glucosamine disaccharide, and Leishmania elongation factor.

42. (Previously Presented) The method of claim 2, wherein the composition is administered simultaneously with said at least one treatment modality which is in admixture with said population of complexes.

43. (Previously Presented) The method of claim 2, which comprises subjecting said protein preparation to digestion with the one or more proteases.

44. (Previously Presented) The method of claim 2, which comprises subjecting said protein preparation to cleavage by the one or more non-enzymatic methods.

45. (Previously Presented) The method of claim 44, wherein the cleavage is cyanogen bromide cleavage.

46. (New) The method of claim 2 or 17, wherein said protein preparation comprises total protein in an organelle fraction, wherein said organelle fraction is a nuclear, mitochondrial, lysosomal or endoplasmic reticulum-derived fraction.

47. (New) The method of claim 43 or 44, wherein the subject is a human.